Naoise Synnott

Dr. Naoise Synnott

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
MDMichael Joseph Duffy
Michael Joseph Duffy
NSNaoise Synnott
Naoise Synnott
JCJohn Crown
John Crown

1 December 2014 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
MDMichael J. Duffy
Michael J. Duffy
NSNaoise Synnott
Naoise Synnott
PMPatricia M. McGowan
Patricia M. McGowan
JCJohn Crown
John Crown
DODarran O’connor
Darran O’connor
WGWilliam M. Gallagher
William M. Gallagher

21 March 2018 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
MDMichael Joseph Duffy
Michael Joseph Duffy
NSNaoise Synnott
Naoise Synnott
JCJohn Crown
John Crown

12 September 2016 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
NSNaoise Synnott
Naoise Synnott
AMA. Murray
A. Murray
PMP.M. McGowan
P.M. McGowan
MKM. Kiely
M. Kiely
PKP.A. Kiely
P.A. Kiely
MDMichael Joseph Duffy
Michael Joseph Duffy
The identification and validation of a targeted therapy for patients with triple‐negative breast cancer (TNBC) is currently one of the most urgent needs in breast cancer therapeutics. One of the key reasons for the failure to develop a new therapy for this subgroup of breast cancer patients has been the difficulty in identifying a highly prevalent, targetable molecular alteration in these tumors. Recently however, the p53 gene was found to be mutated in approximately 80% of basal/TNBC, raising the possibility that targeting the mutant p53 protein product might be a new approach for the treatment of this form of breast cancer. In this study, we investigated the anti‐cancer activity of PRIMA‐1 and PRIMA‐1MET (APR‐246), two compounds which were previously reported to reactivate mutant p53 and convert it to a form with wild‐type (WT) properties. Using a panel of 18 breast cancer cell lines and 2 immortalized breast cell lines, inhibition of proliferation by PRIMA‐1 and PRIMA‐1MET was found to be cell‐line dependent, but independent of cell line molecular subtype. Although response was independent of molecular subtype, p53 mutated cell lines were significantly more sensitive to PRIMA‐1MET than p53 WT cells (p = 0.029). Furthermore, response (measured as IC50 value) correlated significantly with p53 protein level as measured by ELISA (p = 0.0089, r=−0.57, n = 19). In addition to inhibiting cell proliferation, PRIMA‐1MET induced apoptosis and inhibited migration in a p53 mutant‐dependent manner. Based on our data, we conclude that targeting mutant p53 with PRIMA‐1MET is a potential new approach for treating p53‐mutated breast cancer, including the subgroup with triple‐negative (TN) disease.

1 April 2017 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
MDMichael Joseph Duffy
Michael Joseph Duffy
AMAlyson Murray
Alyson Murray
NSNaoise Synnott
Naoise Synnott
NONorma O’donovan
Norma O’donovan
JCJohn Crown
John Crown

19 September 2019 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
NSNaoise Synnott
Naoise Synnott
DOdavid o'connell
david o'connell
JCJohn Crown
John Crown
MDMichael Joseph Duffy
Michael Joseph Duffy